NCT02400788View on ClinicalTrials.gov

Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

179

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

June 30, 2016

Study Completion Date

October 31, 2016

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Resminostat

DRUG

Sorafenib

Trial Locations (12)

Unknown

Chiba

Ishikawa

Kanagawa

Kochi

Kyoto

Osaka

Saga

Shizuoka

Tokyo

Busan

Daegu

Seoul

All Listed Sponsors

lead

Yakult Honsha Co., LTD

INDUSTRY

NCT02400788 - Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter